In summary, we conducted a multi-center, multiple-dose drug interaction study to investigate the inhibitory potential of the ALK-inhibitor ceritinib towards 2 clinically relevant CYP enzymes, 3A4 and 2C9, using a 2-drug cocktail probe approach in 33 cancer patients representative of the target population of ceritinib. The gene discussed is PPIG; the disease is cancer.